December 30, 2022 at 05:02PM FY 2019 Report from the Director

Fiscal Year 2019 was an exciting time at CBER, as we continued to conduct important mission-oriented research and approved important new products that protect and improve public health. These included a novel gene therapy, vaccines, treatments for immune deficiencies, and tests for protection of the

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/sMuPnKB